{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:19:07Z","timestamp":1774084747861,"version":"3.50.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.diagmicrobio.2006.11.020","type":"journal-article","created":{"date-parts":[[2007,2,10]],"date-time":"2007-02-10T07:13:30Z","timestamp":1171091610000},"page":"S55-S65","source":"Crossref","is-referenced-by-count":22,"special_numbering":"S","title":["Oral \u03b2-lactams applied to uncomplicated infections of skin and skin structures"],"prefix":"10.1016","volume":"57","author":[{"given":"Michael R.","family":"Jacobs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip A.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/jac\/dkg100","article-title":"Significant increase in the prevalence of erythromycin-resistant, clindamycin- and miocamycin-susceptible (M phenotype) Streptococcus pyogenes in Spain","volume":"51","author":"Alos","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib2","series-title":"Practical Statistics for Medical Research","author":"Altman","year":"1991"},{"issue":"Suppl. 1","key":"10.1016\/j.diagmicrobio.2006.11.020_bib3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1469-0691.2006.01344.x","article-title":"The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus","volume":"12","author":"Appelbaum","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0197-2456(82)90024-1","article-title":"\u201cProving the null hypothesis\u201d in clinical trials","volume":"3","author":"Blackwelder","year":"1982","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0197-2456(84)90116-8","article-title":"Sample size graphs for \u201cproving the null hypothesis\u201d","volume":"5","author":"Blackwelder","year":"1984","journal-title":"Control Clin. Trials"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1469-0691.2003.00598.x","article-title":"Activity of telithromycin compared with seven other agents against 1,039 Streptococcus pyogenes pediatric isolates from ten centers in central and eastern Europe","volume":"9","author":"Bozdogan","year":"2003","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib7","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0149-2918(02)80024-8","article-title":"Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections","volume":"24","author":"Bucko","year":"2002","journal-title":"Clin. Ther."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jac\/dkg359","article-title":"Comparative activity of telithromycin against typical community-acquired respiratory pathogens","volume":"52","author":"Buxbaum","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1590\/S0036-36342002000200004","article-title":"Epidemiology of drug resistance: the case of Staphylococcus aureus and coagulase-negative staphylococci infections","volume":"44","author":"Calderon-Jaimes","year":"2002","journal-title":"Salud Publica Mex."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib10","series-title":"Physician's Desk Reference","first-page":"1829","author":"Ceclor","year":"2004"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib11","series-title":"Physicians' Desk Reference","first-page":"1450","author":"Ceftin","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib12","series-title":"Physicians' Desk Reference","first-page":"1037","author":"Cefzil","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib13","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1128\/AAC.48.6.2049-2055.2004","article-title":"Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY Program, 1999 to 2001","volume":"48","author":"Christiansen","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib14","series-title":"Clinical and Laboratory Standards Institute. M100-S16, Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement","author":"CLSI","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/BF02017363","article-title":"Exogenous thymidine and reversal of the inhibitory effect of sulfamethoxazole\u2013trimethoprim on streptococci","volume":"3","author":"Coll","year":"1984","journal-title":"Eur. J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of \u03b2-lactams, glycopeptides, and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00006454-199702000-00012","article-title":"Oral antibiotic therapy for uncomplicated bacterial skin infections in children","volume":"16","author":"Darmstadt","year":"1997","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"Suppl. 2","key":"10.1016\/j.diagmicrobio.2006.11.020_bib19","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1086\/320184","volume":"32","author":"Diekema","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0163-4453(03)00123-3","article-title":"Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01","volume":"48","author":"Doern","year":"2004","journal-title":"J. Infect."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib21","series-title":"Physicians' Desk Reference","first-page":"3291","author":"Duricef","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib22","author":"Duricef Package Insert","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0732-8893(97)00060-6","article-title":"In vitro activity of trimethoprim alone compared with trimethoprim\u2013sulfamethoxazole and other antimicrobials against bacterial species associated with upper respiratory tract infections","volume":"29","author":"Eliopoulos","year":"1997","journal-title":"Diagn. Microbiol. Infect Dis."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib24","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-133-6-200009190-00015","article-title":"Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: Practical issues and specific cases","volume":"133","author":"Ellenberg","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib25","author":"EMEA"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib26","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1128\/AAC.24.5.679","article-title":"Amoxicillin combined with clavulanic acid for the treatment of soft tissue infections in children","volume":"24","author":"Fleisher","year":"1983","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib27","first-page":"s4","article-title":"Importance of understanding pharmacokinetic\/pharmacodynamic principles in the emergence of resistances, including community-associated Staphylococcus aureus","volume":"4","author":"Fritsche","year":"2005","journal-title":"J. Durgs Dermatol."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0732-8893(03)00114-7","volume":"47","author":"Fritsche","year":"2003","journal-title":"Diagn. Microbiol. Infect Dis."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib29","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1185\/030079906X148355","article-title":"Cefdinir versus cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults","volume":"22","author":"Giordano","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib30","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1001\/archinte.1965.03870030020005","article-title":"Dicloxacillin. In vitro and pharmacologic comparisons with oxacillin and cloxacillin","volume":"116","author":"Gravenkemper","year":"1965","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib31","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMe068152","article-title":"The treatment triangle for staphylococcal infections","volume":"355","author":"Grayson","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib32","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/00006454-199208001-00005","article-title":"Loracarbef vs. cefaclor in pediatric skin and skin structure infections","volume":"11","author":"Hanfling","year":"1992","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"Suppl. 1","key":"10.1016\/j.diagmicrobio.2006.11.020_bib33","first-page":"35","article-title":"Acute bacterial skin infections in pediatric medicine: current issues in presentation and treatment","volume":"5","author":"Hedrick","year":"2003","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0732-8893(02)00522-9","article-title":"Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999\u20132000: findings of the PROTEKT Surveillance Study","volume":"45","author":"Hoban","year":"2003","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib35","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1128\/AAC.47.7.2152-2157.2003","article-title":"Telithromycin and quinupristin\u2013dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 Data","volume":"47","author":"Hsueh","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/bimj.200410084","article-title":"A regulatory perspective on choice of margin and statistical inference issue in non-inferiority trials","volume":"47","author":"Hung","year":"2005","journal-title":"Biom. Z."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib37","first-page":"240","article-title":"Comparison of azithromycin and cefadroxil for the treatment of uncomplicated skin and skin structure infections","volume":"72","author":"Jennings","year":"2003","journal-title":"Cutis"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1476-0711-3-14","article-title":"Emerging resistance among bacterial pathogens in the intensive care unit\u2014a European and North American Surveillance study (2000\u20132002)","volume":"3","author":"Jones","year":"2004","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib39","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10096-004-1133-5","article-title":"Rates of antimicrobial resistance among common bacterial pathogens causing respiratory, blood, urine, and skin and soft tissue infections in pediatric patients","volume":"23","author":"Jones","year":"2004","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib40","article-title":"Molecular characterization of S. aureus (SA) isolates from a contemporary (2005) clinical trial of uncomplicated skin and skin structure infections (uSSSI)","author":"Jones","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib41","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1097\/01.inf.0000087020.75886.93","article-title":"Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children","volume":"22","author":"Kaplan","year":"2003","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib42","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1128\/AAC.47.7.2370-2372.2003","article-title":"Emergence of macrolide resistance in throat culture isolates of group A streptococci in Ontario, Canada, in 2001","volume":"47","author":"Katz","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib43","series-title":"Physicians' Desk Reference","first-page":"1871","author":"Keflex","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib44","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1128\/AAC.48.4.1124-1127.2004","article-title":"In vitro activities of 28 antimicrobial agents against Staphylococcus aureus isolates from tertiary-care hospitals in Korea: a nationwide survey","volume":"48","author":"Kim","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib45","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00002512-200219050-00002","article-title":"Bacterial skin infections in the elderly: diagnosis and treatment","volume":"19","author":"Laube","year":"2002","journal-title":"Drugs Aging"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/01.inf.0000109288.06912.21","article-title":"Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus","volume":"23","author":"Lee","year":"2004","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib47","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/jcp.56.5.344","article-title":"National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents","volume":"56","author":"Liebowitz","year":"2003","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib48","author":"Lin"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib49","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0022-3476(05)80601-8","article-title":"Measuring the comparative efficacy of antibacterial agents for acute otitis media: the \u201cPollyanna phenomenon\u201d","volume":"120","author":"Marchant","year":"1992","journal-title":"J. Pediatr."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1590\/S1413-86702003000100006","article-title":"Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT Surveillance Study (1999\u20132000)","volume":"7","author":"Mendes","year":"2003","journal-title":"Braz. J. Infect. Dis."},{"issue":"Suppl","key":"10.1016\/j.diagmicrobio.2006.11.020_bib51","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jac\/37.suppl_C.125","article-title":"A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and\/or soft tissue infections","volume":"37","author":"Montero","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib52","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMoa055356","article-title":"Methicillin-resistant S. aureus infections among patients in the emergency department","volume":"355","author":"Moran","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib53","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/BF02111354","article-title":"Comparative studies of cefprozil in the management of skin and soft-tissue infections","volume":"13","author":"Nolen","year":"1994","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib54","series-title":"Physicians' Desk Reference","first-page":"506","author":"Omnicef","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib55","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.coph.2006.06.002","article-title":"Anti-MRSA beta-lactams in development","volume":"6","author":"Page","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib56","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1742-1241.2000.tb10911.x","article-title":"Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections","volume":"54","author":"Parish","year":"2000","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib57","doi-asserted-by":"crossref","first-page":"155S","DOI":"10.1016\/S0002-9343(20)31157-8","article-title":"Open trial of oral fleroxacin versus amoxicillin\/clavulanate in the treatment of infections of skin and soft tissue","volume":"94","author":"Powers","year":"1993","journal-title":"Am. J. Med."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib58","first-page":"s9","article-title":"Update on treating uncomplicated skin and skin structure infections","volume":"4","author":"Rosen","year":"2005","journal-title":"J. Durgs Dermatol."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib59","author":"SISA"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib60","doi-asserted-by":"crossref","first-page":"150S","DOI":"10.1016\/S0002-9343(20)31156-6","article-title":"Comparison of oral fleroxacin with oral amoxicillin\/clavulanate for treatment of skin and soft tissue infections","volume":"94","author":"Smith","year":"1993","journal-title":"Am. J. Med."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib61","series-title":"Physicians' Desk Reference","first-page":"2824","author":"Spectracef","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0732-8893(93)90006-S","article-title":"Comparison of oral cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections","volume":"16","author":"Stevens","year":"1993","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib63","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1086\/497143","article-title":"Practice guidelines for the diagnosis and management of skin and soft-tissue infections","volume":"41","author":"Stevens","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib64","first-page":"119","article-title":"Common bacterial skin infections","volume":"66","author":"Stulberg","year":"2002","journal-title":"Am. Fam. Phys."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib65","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1128\/AAC.41.4.739","article-title":"Study of use of cefdinir versus cephalexin for treatment of skin infections in pediatric patients. The Cefdinir Pediatric Skin Infection Study Group","volume":"41","author":"Tack","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib66","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0149-2918(98)80088-X","article-title":"Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. The Cefdinir Adult Skin Infection Study Group","volume":"20","author":"Tack","year":"1998","journal-title":"Clin. Ther."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib67","doi-asserted-by":"crossref","first-page":"159S","DOI":"10.1016\/S0002-9343(20)31158-X","article-title":"Comparative efficacy and safety of oral fleroxacin and amoxicillin\/clavulanate potassium in skin and soft tissue infections","volume":"94","author":"Tassler","year":"1993","journal-title":"Am. J. Med."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib68","author":"Temple"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib69","doi-asserted-by":"crossref","first-page":"455","DOI":"10.7326\/0003-4819-133-6-200009190-00014","article-title":"Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues","volume":"133","author":"Temple","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib70","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/bmj.317.7162.875","article-title":"When placebo controlled trials are essential and equivalence trials are inadequate","volume":"317","author":"Tramer","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib71","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3201\/eid0908.030089","article-title":"Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton\u2013Valentine leukocidin genes: worldwide emergence","volume":"9","author":"Vandenesch","year":"2003","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib72","series-title":"Physicians' Desk Reference","first-page":"2758","author":"Vantin","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib73","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/01.SMJ.0000091066.74656.6C","article-title":"Antimicrobial resistance among isolates of respiratory tract infection pathogens from the Southern United States: data from the PROTEKT US Surveillance Program 2000\/2001","volume":"96","author":"Waites","year":"2003","journal-title":"South Med. J."},{"key":"10.1016\/j.diagmicrobio.2006.11.020_bib74","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/01.inf.0000059403.21440.2c","article-title":"Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children","volume":"22","author":"Wible","year":"2003","journal-title":"Pediatr. Infect. Dis. J."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889306004767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889306004767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T14:00:11Z","timestamp":1683727211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889306004767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0732889306004767"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2006.11.020","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}